论文部分内容阅读
【据《J Hepatol》2015年5月报道】题:慢性乙型肝炎患者HBsA g血清清除后肝细胞癌的发生率:需要监测(作者Kim GA等)对于HBsA g血清清除的慢性乙型肝炎患者,是否该继续监测肝细胞癌的发生,这方面的研究很少。蔚山大学医学院的Kim GA等回顾性分析了1997-2012年韩国三级医院达到了HBsA g血清清除的829例患者(平均年龄52.3岁,575例男性,98例合并有肝硬化)的资料。他们评估了肝癌的发生率并验证了基于HBsA g血清清除时间点的CU-HCC肝癌风险评分。结果显示在3464随访人年中,19例患者发展为肝癌(年发生
According to “J Hepatol” May 2015 Report Title: The incidence of hepatocellular carcinoma after HBsA g serum clearance in patients with chronic hepatitis B: need monitoring (by Kim GA et al.) In patients with chronic hepatitis B who have HBsA g serum clearance , Whether to continue to monitor the occurrence of hepatocellular carcinoma, few studies in this area. Kim GA, Ulsan University School of Medicine retrospectively analyzed 829 patients (mean age 52.3 years, 575 males, 98 with cirrhosis) who achieved HBsA g serum clearance at tertiary hospitals in Korea in 1997-2012. They evaluated the incidence of liver cancer and validated the CU-HCC liver cancer risk score based on the HBsA g serum clearance time point. The results showed that in the 3464 follow-up years, 19 patients developed liver cancer (annual incidence